Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | TAF1 | P21675 | 1/20 | 0.36 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8620419 | 0.78 | USP2 (0.48) | ALOX15USP2GAARAD51NPSR1 | |
| SCHEMBL4798726 | 0.78 | CYP1A2 (0.40) | BRD4TAF1BRPF1CREBBPCECR2 | |
| SCHEMBL4484912 | 0.77 | AHR (0.47) | BRD4TAF1BRPF1CREBBPCECR2 | |
| SCHEMBL3584001 | 0.75 | AHR (0.45) | MAOABRD4TAF1BRPF1CREBBP | |
| SCHEMBL2983533 | 0.75 | ALDH1A1 (0.38) | BRD4TAF1BRPF1CREBBPCECR2 | |
| SCHEMBL2599709 | 0.75 | AHR (0.45) | BRD4TAF1BRPF1CREBBPCECR2 | |
| SCHEMBL17064186 | 0.75 | AHR (0.50) | ALOX15USP2GAARAD51NPSR1 | |
| SCHEMBL1960195 | 0.75 | USP2 (0.45) | ALOX15USP2GAARAD51NPSR1 | |
| SCHEMBL5372066 | 0.75 | ALOX15 (0.45) | ALOX15USP2GAARAD51NPSR1 | |
| SCHEMBL23735763 | 0.75 | USP2 (0.41) | ALOX15USP2GAARAD51NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120118068-A | Chemical process for preparing phenylpiperidinyl indole derivatives | 诺华股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-112513025-B | Chemical process for preparing phenylpiperidinyl indole derivatives | 诺华股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-11578053-B2 | Chemical process for preparing phenylpiperidinyl indole derivatives | NOVARTIS AG (CH) | 2023-02-14 | — | — | US | disclosed |
| US-20220169630-A1 | CHEMICAL PROCESS FOR PREPARING PHENYLPIPERIDINYL INDOLE DERIVATIVES | NOVARTIS AG (CH) | 2022-06-02 | — | — | US | disclosed |
| US-11208398-B2 | Chemical process for preparing phenylpiperidinyl indole derivatives | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| US-11208398-B2 | Chemical process for preparing phenylpiperidinyl indole derivatives | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| EP-3558955-B1 | BENZISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | AMGEN INC (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3823963-A2 | CHEMICAL PROCESS FOR PREPARING PHENYLPIPERIDINYL INDOLE DERIVATIVES | Novartis AG (CH) | 2021-05-26 | — | — | EP | disclosed |
| CN-112513025-A | Chemical process for the preparation of phenylpiperidinylindole derivatives | 诺华股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
| WO-2020016749-A2 | CHEMICAL PROCESS FOR PREPARING PHENYLPIPERIDINYL INDOLE DERIVATIVES | NOVARTIS AG (CH) | 2020-01-23 | — | — | WO | disclosed |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-12-31 | — | — | US | disclosed |
| CN-101547927-A | 8-sulfonyl-l, 3, 4, 8-tetrahydr0-2h- [1, 4] oxazepino [6, 7-e] indole derivatives and their use as 5-ht6 receptor ligands | BIOVITRUM AB PUBL (SE) | 2009-09-30 | — | — | CN | disclosed |
| EP-2091953-A1 | 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4]OXAZEPINO [6, 7-E]INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS | BIOVITRUM AB (publ) (SE) | 2009-08-26 | — | — | EP | disclosed |
| EP-2017263-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-2017263-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20080176829-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2008-07-24 | — | — | US | disclosed |
| WO-2008054288-A1 | 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4] OXAZEPINO [6, 7-E] INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS | BIOVITRUM AB (PUBL) (SE) | 2008-05-08 | — | — | WO | disclosed |
| US-5736534-A | HYPERPROLIFERATIVE DISEASES; INHIBITORS OF PROTEIN-TYROSINE KINASES SUCH AS EPIDERMAL GROWTH FACTOR RECEPTOR; BRAIN, LUNG, BREAST CANCER; PSORIASIS AND BENIGN PROSTATE HYPERPLASIA | PFIZER INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0746554-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995023141-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169630-A1 | CHEMICAL PROCESS FOR PREPARING PHENYLPIPERIDINYL INDOLE DERIVATIVES | IDO1, CYP3A7, PAH | ALOX15 1674/4885USP2 4259/4885GAA 1778/4885 |
| US-20080176829-A1 | Compounds | HTR6, HTR1B, HTR1A | ALOX15 739/4885USP2 4643/4885GAA 1443/4885 |
| US-11208398-B2 | Chemical process for preparing phenylpiperidinyl indole derivatives | CYP3A7, CYP3A5, IDO1 | ALOX15 1740/4885USP2 4261/4885GAA 1836/4885 |
| US-20090324581-A1 | HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE | S1PR3, S1PR2, S1PR1 | ALOX15 683/4885USP2 4456/4885GAA 4259/4885 |
| US-11578053-B2 | Chemical process for preparing phenylpiperidinyl indole derivatives | IDO1, CYP3A7, PAH | ALOX15 1674/4885USP2 4259/4885GAA 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.